BC057079 Inhibitors
BC057079, an intriguing protein, is implicated in cellular processes associated with inflammation, immune responses, and cell survival. Despite ongoing investigations, its precise function remains to be fully elucidated. The intricate regulatory networks that converge on BC057079 make it a compelling target for research focused on understanding fundamental cellular processes. Ruxolitinib, a JAK1/2 inhibitor, and Tofacitinib, a JAK1/3 inhibitor, disrupt the JAK/STAT pathway, offering insights into potential regulatory mechanisms. These compounds interfere with signaling cascades associated with inflammation and immune responses, suggesting a role in modulating BC057079 expression and function. Dasatinib, a Src/Abl kinase inhibitor, and Lapatinib, a dual EGFR/HER2 inhibitor, target kinase pathways linked to proliferation and survival, providing additional avenues for potential modulation of BC057079.
SB202190, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, influence MAPK signaling pathways, indicating potential modulation of BC057079 expression and function in specific cellular contexts. Imatinib, an Abl kinase inhibitor, and VX-680, an Aurora kinase inhibitor, provide further insights into potential regulatory mechanisms associated with cell division and proliferation. 2'-Deoxy-2',2'-difluorocytidine, a nucleoside analog, and Nutlin-3, an MDM2 inhibitor, impact DNA replication and the p53 pathway, respectively, suggesting potential indirect modulation of BC057079 expression and function. Cisplatin, a DNA cross-linking agent, induces DNA damage, activating signaling pathways that may influence BC057079 indirectly. In conclusion, BC057079 inhibitors present valuable tools for unraveling the intricacies of this protein's function and the regulatory networks that govern it. As research advances, a comprehensive understanding of BC057079 and its modulation by these inhibitors will undoubtedly contribute to our knowledge of fundamental cellular processes, paving the way for future discoveries in inflammation, immune responses, and cell survival.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor. Ruxolitinib disrupts the JAK/STAT pathway, potentially influencing BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with inflammation and immune responses. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src/Abl kinase inhibitor. Dasatinib targets Src and Abl kinases, potentially influencing BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with proliferation and survival. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
DNA cross-linking agent. Cisplatin induces DNA damage, activating signaling pathways that may influence BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with DNA repair and cell survival. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR/HER2 inhibitor. Lapatinib targets EGFR and HER2, potentially influencing BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with proliferation and survival. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
p38 MAPK inhibitor. SB202190 influences the p38 MAPK pathway, potentially modulating BC057079 expression and function in specific cellular contexts. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Abl kinase inhibitor. Imatinib targets Abl kinase, potentially influencing BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with proliferation and survival. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
2'-Deoxy-2',2'-difluorocytidine incorporates into DNA, affecting DNA synthesis and repair pathways that may influence BC057079 indirectly. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Tozasertib targets Aurora kinases, potentially influencing BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with cell division and proliferation. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Multi-targeted receptor tyrosine kinase inhibitor. Sunitinib targets multiple receptors, potentially influencing BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with angiogenesis and cell survival. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor. SP600125 disrupts the JNK signaling pathway, potentially influencing BC057079 indirectly. This interference may impact BC057079 expression and function, altering cellular processes associated with inflammation and stress responses. | ||||||